Ardelyx (ARDX) Change in Accured Expenses (2013 - 2026)
Ardelyx posted quarterly Change in Accured Expenses of $19.0 million for Q1 2026, up 344.75% year-on-year from $4.3 million in Q1 2025, and up 681.51% on a QoQ basis from $2.4 million in Q4 2025.
Ardelyx (ARDX) has 14 years of Change in Accured Expenses data on file, last reported at $19.0 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Accured Expenses rose 344.75% year-over-year to $19.0 million; the trailing twelve-month figure through Mar 2026 stood at $41.3 million (up 113.62% YoY), and the FY2025 full-year result was $14.5 million, down 31.57% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $19.0 million, up from $2.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $19.0 million in Q1 2026 and bottomed at -$7.8 million in Q1 2025.
- The 5-year median for Change in Accured Expenses is $2.0 million (2022), against an average of $3.8 million.
- Peak annual rise in Change in Accured Expenses reached 1083.07% in 2024, while the deepest fall reached 320.49% in 2024.
- A 5-year view of Change in Accured Expenses shows it stood at $2.4 million in 2022, then surged by 77.04% to $4.2 million in 2023, then plunged by 63.23% to $1.6 million in 2024, then surged by 56.13% to $2.4 million in 2025, then jumped by 681.51% to $19.0 million in 2026.
- The last three Change in Accured Expenses figures came in at $19.0 million (Q1 2026), $2.4 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Ardelyx | 1.48 Bn | 1.25 Bn | 89.66 Mn | 19.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19.02 Mn |
| Mar 31, 2026 | 19.02 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Sep 30, 2025 | 4.63 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Jun 30, 2025 | 15.25 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Mar 31, 2025 | -7.77 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Dec 31, 2024 | 1.56 Mn |
| Sep 30, 2024 | 7.75 Mn |
| Sep 30, 2024 | 7.75 Mn |
| Jun 30, 2024 | 17.82 Mn |
| Jun 30, 2024 | 17.82 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Mar 31, 2024 | -5.87 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Dec 31, 2023 | 4.24 Mn |
| Sep 30, 2023 | 699,000.00 |
| Sep 30, 2023 | 699,000.00 |
| Jun 30, 2023 | 1.51 Mn |
| Jun 30, 2023 | 1.51 Mn |
| Mar 31, 2023 | -1.40 Mn |
| Mar 31, 2023 | -1.40 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 760,000.00 |
| Sep 30, 2022 | 760,000.00 |
| Jun 30, 2022 | 2.02 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | -1.04 Mn |
| Mar 31, 2022 | -1.04 Mn |
| Dec 31, 2021 | 652,000.00 |
| Dec 31, 2021 | 652,000.00 |
| Sep 30, 2021 | -3.51 Mn |
| Sep 30, 2021 | -3.51 Mn |
| Jun 30, 2021 | -4.91 Mn |
| Jun 30, 2021 | -4.91 Mn |
| Mar 31, 2021 | 7.52 Mn |
| Mar 31, 2021 | 7.52 Mn |
| Dec 31, 2020 | 1.95 Mn |
| Dec 31, 2020 | 1.95 Mn |
| Sep 30, 2020 | -905,000.00 |
| Sep 30, 2020 | -905,000.00 |
| Jun 30, 2020 | 2.68 Mn |
| Jun 30, 2020 | 2.68 Mn |
| Mar 31, 2020 | -2.50 Mn |
| Mar 31, 2020 | -2.50 Mn |
| Dec 31, 2019 | 4.97 Mn |
| Dec 31, 2019 | 4.97 Mn |
| Sep 30, 2019 | -2.87 Mn |
| Sep 30, 2019 | -2.87 Mn |
| Jun 30, 2019 | 717,000.00 |
| Jun 30, 2019 | 717,000.00 |
| Mar 31, 2019 | -1.09 Mn |
| Mar 31, 2019 | -1.09 Mn |
| Dec 31, 2018 | 2.28 Mn |
| Dec 31, 2018 | 2.28 Mn |
| Sep 30, 2018 | 103,000.00 |
| Sep 30, 2018 | 103,000.00 |
| Jun 30, 2018 | 586,000.00 |
| Jun 30, 2018 | 586,000.00 |
| Mar 31, 2018 | -1.61 Mn |
| Mar 31, 2018 | -1.61 Mn |
| Dec 31, 2017 | -771,000.00 |
| Dec 31, 2017 | -771,000.00 |
| Sep 30, 2017 | 1.40 Mn |
| Sep 30, 2017 | 1.40 Mn |
| Jun 30, 2017 | 743,000.00 |
| Jun 30, 2017 | 743,000.00 |
| Mar 31, 2017 | -1.31 Mn |
| Mar 31, 2017 | -1.31 Mn |
| Dec 31, 2016 | 8.42 Mn |
| Dec 31, 2016 | 8.42 Mn |
| Sep 30, 2016 | 189,000.00 |
| Sep 30, 2016 | 189,000.00 |
| Jun 30, 2016 | 719,000.00 |
| Jun 30, 2016 | 719,000.00 |
| Mar 31, 2016 | -1.05 Mn |
| Mar 31, 2016 | -1.05 Mn |
| Dec 31, 2015 | -6.91 Mn |
| Dec 31, 2015 | -6.91 Mn |
| Sep 30, 2015 | 6.74 Mn |
| Sep 30, 2015 | 6.74 Mn |
| Jun 30, 2015 | 1.59 Mn |
| Jun 30, 2015 | 1.59 Mn |
| Mar 31, 2015 | -703,000.00 |
| Mar 31, 2015 | -703,000.00 |
| Dec 31, 2014 | -57,000.00 |
| Dec 31, 2014 | -57,000.00 |
| Sep 30, 2014 | 304,000.00 |
| Sep 30, 2014 | 304,000.00 |
| Jun 30, 2014 | 201,000.00 |
| Jun 30, 2014 | 201,000.00 |
| Mar 31, 2014 | -326,000.00 |
| Mar 31, 2014 | -326,000.00 |
| Dec 31, 2013 | 206,000.00 |
| Dec 31, 2013 | 206,000.00 |
| Sep 30, 2013 | 133,000.00 |
| Sep 30, 2013 | 133,000.00 |